2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 15:26, 21 November 2023
, 21 November 2023→Clinical Trials
| Line 310: | Line 310: | ||
*Adverse events similar between groups | *Adverse events similar between groups | ||
*Provides rationale for larger trials on NAD augmentation for cardiometabolic outcomes in older adults | *Provides rationale for larger trials on NAD augmentation for cardiometabolic outcomes in older adults | ||
|- | |||
|{{pmid text|35927255}} | |||
| | |||
| | |||
| | |||
|} | |} | ||